HRP20161740T1 - Ljudske molekule za vezanje koje su sposobne neutralizirati viruse influence a filogenetske skupine 1 i filogenetske skupine 2, te viruse influence b - Google Patents

Ljudske molekule za vezanje koje su sposobne neutralizirati viruse influence a filogenetske skupine 1 i filogenetske skupine 2, te viruse influence b

Info

Publication number
HRP20161740T1
HRP20161740T1 HRP20161740TT HRP20161740T HRP20161740T1 HR P20161740 T1 HRP20161740 T1 HR P20161740T1 HR P20161740T T HRP20161740T T HR P20161740TT HR P20161740 T HRP20161740 T HR P20161740T HR P20161740 T1 HRP20161740 T1 HR P20161740T1
Authority
HR
Croatia
Prior art keywords
seq
region
heavy chain
light chain
influenza
Prior art date
Application number
HRP20161740TT
Other languages
English (en)
Inventor
Theodorus Hendrikus Jacobus Kwaks
David A.T.M. Zuijdgeest
Ronald Vogels
Robert Heinz Edward Friesen
Original Assignee
Janssen Vaccines & Prevention B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Vaccines & Prevention B.V. filed Critical Janssen Vaccines & Prevention B.V.
Publication of HRP20161740T1 publication Critical patent/HRP20161740T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/11—Orthomyxoviridae, e.g. influenza virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)

Claims (7)

1. Izolirano antitijelo ili njegov fragment koji veže antigen, koje je sposobno specifično vezati na epitop u matičnoj regiji proteina hemaglutinina (HA) podtipove virusa influence A filogenetske skupine 1 i podtipove virusa influence A filogenetske skupine 2, te je sposobno neutralizirati barem jedan ili više podtipova virusa influence A skupina 1, koji se biraju iz skupine koja sadrži viruse influence A koji sadrže HA podtip H1, H2, H5, H6, H8, H9 i H11, te barem jedan ili više podtipova virusa influence A skupine 2, koji se biraju iz skupine koja sadrži viruse influence A koji sadrže HA podtip H3, H4, H7, i H10, naznačeno time da antitijelo ili njegov fragment koji veže antigen je također sposoban specifično se vezati na protein hemaglutinina (HA) podtipova virusa influence B.
2. Antitijelo ili njegov fragment koji veže antigen prema zahtjevu 1, naznačeno time da antitijelo ili njegov fragment koji veže antigen nema inhibirajuću aktivnost hemaglutinacije.
3. Antitijelo ili njegov fragment koji veže antigen prema bilo kojem od prethodnih zahtjeva, naznačeno time da se antitijelo ili njegov fragment koji veže antigen bira iz skupine koju čine: antitijelo ili njegov fragment koji veže antigen sadrži regiju teškog lanca CDR1 od SEQ ID NO: 139, regiju teškog lanca CDR2 od SEQ ID NO:134, i regiju teškog lanca CDR3 od SEQ ID NO:145, i regiju lakog lanca CDR1 od SEQ ID NO: 146, regiju lakog lanca CDR2 od SEQ ID NO: 174, i regiju lakog lanca CDR3 od SEQ ID NO: 147, regiju teškog lanca CDR1 od SEQ ID NO:139, regiju teškog lanca CDR2 od SEQ ID NO:134, i regiju teškog lanca CDR3 od SEQ ID NO:145, i regiju lakog lanca CDR1 od SEQ ID NO:148, regiju lakog lanca CDR2 od SEQ ID NO: 149, i regiju lakog lanca CDR3 od SEQ ID NO:150, regiju teškog lanca CDR1 od SEQ ID NO:139, regiju teškog lanca CDR2 od SEQ ID NO:134, i regiju teškog lanca CDR3 od SEQ ID NO:145, i regiju lakog lanca CDR1 od SEQ ID NO:142, regiju lakog lanca CDR2 od SEQ ID NO:143, i regiju lakog lanca CDR3 od SEQ ID NO:173; antitijelo ili njegov fragment koji veže antigen sadrži regiju teškog lanca CDR1 od SEQ ID NO:139, regiju teškog lanca CDR2 od SEQ ID NO: 134, i regiju teškog lanca CDR3 od SEQ ID N0:152, i regiju lakog lanca CDR1 od SEQ ID NO:148, regiju lakog lanca CDR2 od SEQ ID NO:149, i regiju lakog lanca CDR3 od SEQ ID NO:150, regiju teškog lanca CDR1 od SEQ ID NO:139, regiju teškog lanca CDR2 od SEQ ID NO:134, i regiju teškog lanca CDR3 od SEQ ID N0:152, i regiju lakog lanca CDR1 od SEQ ID NO: 156, regiju lakog lanca CDR2 od SEQ ID NO: 157, i regiju lakog lanca CDR3 od SEQ ID NO: 158, regiju teškog lanca CDR1 od SEQ ID NO:139, regiju teškog lanca CDR2 od SEQ ID NO:130 i regiju teškog lanca CDR3 od SEQ ID NO:152, i regiju lakog lanca CDR1 od SEQ ID NO:171, regiju lakog lanca CDR2 od SEQ ID NO:164, i regiju lakog lanca CDR3 od SEQ ID NO:172, i regiju teškog lanca CDR1 od SEQ ID NO:139, regiju teškog lanca CDR2 od SEQ ID NO: 134, i regiju teškog lanca CDR3 od SEQ ID N0:152, i regiju lakog lanca CDR1 od SEQ ID NO: 142, regiju lakog lanca CDR2 od SEQ ID NO: 143, i regiju lakog lanca CDR3 od SEQ ID NO: 144.
4. Molekula nukleinske kiseline, naznačena time da kodira antitijelo ili njegov fragment koji veže antigen prema bilo kojem od zahtjeva 1-3.
5. Antitijelo ili njegov fragment koji veže antigen prema bilo kojem od zahtjeva 1-3, i/ili molekulu nukleinske kiseline prema zahtjevu 4, naznačeno time da je za uporabu kao lijek.
6. Antitijelo ili njegov fragment koji veže antigen prema zahtjevu 5, naznačeno time da je za uporabu za profilaksu i/ili terapeutsko liječenje infekcije influencom.
7. Farmaceutski pripravak, naznačen time da sadrži antitijelo ili njegov fragment koji veže antigen prema bilo kojem od zahtjeva 1-3, i/ili molekulu nukleinske kiseline prema zahtjevu 4, te farmaceutski prihvatljivo pomoćno sredstvo.
HRP20161740TT 2011-07-14 2016-12-19 Ljudske molekule za vezanje koje su sposobne neutralizirati viruse influence a filogenetske skupine 1 i filogenetske skupine 2, te viruse influence b HRP20161740T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161572417P 2011-07-14 2011-07-14
EP11173953 2011-07-14
EP12735516.2A EP2731967B1 (en) 2011-07-14 2012-07-12 Human binding molecules capable of neutralizing influenza a viruses of phylogenetic group 1 and phylogenetic group 2 and influenza b viruses
PCT/EP2012/063637 WO2013007770A1 (en) 2011-07-14 2012-07-12 Human binding molecules capable of neutralizing influenza a viruses of phylogenetic group 1 and phylogenetic group 2 and influenza b viruses

Publications (1)

Publication Number Publication Date
HRP20161740T1 true HRP20161740T1 (hr) 2017-02-10

Family

ID=47505543

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20161740TT HRP20161740T1 (hr) 2011-07-14 2016-12-19 Ljudske molekule za vezanje koje su sposobne neutralizirati viruse influence a filogenetske skupine 1 i filogenetske skupine 2, te viruse influence b

Country Status (17)

Country Link
US (2) US8961978B2 (hr)
EP (1) EP2731967B1 (hr)
JP (1) JP5683752B2 (hr)
KR (1) KR101941724B1 (hr)
CN (1) CN103906763B (hr)
AU (1) AU2012282504B2 (hr)
BR (1) BR112014000263B1 (hr)
CA (1) CA2838999C (hr)
DK (1) DK2731967T3 (hr)
EA (1) EA027054B1 (hr)
ES (1) ES2608321T3 (hr)
HR (1) HRP20161740T1 (hr)
IL (1) IL230222A (hr)
IN (1) IN2014CN00953A (hr)
MX (1) MX346206B (hr)
MY (1) MY166282A (hr)
WO (1) WO2013007770A1 (hr)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013007770A1 (en) 2011-07-14 2013-01-17 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza a viruses of phylogenetic group 1 and phylogenetic group 2 and influenza b viruses
CA2857087C (en) 2011-11-28 2021-05-25 Crucell Holland B.V. Influenza virus vaccines and uses thereof
DK2793945T3 (en) 2011-12-05 2018-09-03 Trellis Bioscience Llc USEFUL ANTIBODIES FOR PASSIVE INFLUENZA IMMUNIZATION
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
AU2014236508A1 (en) 2013-03-14 2015-09-17 Contrafect Corporation Composition and methods based on neutralizing antibodies delivered intranasally for enhanced therapeutic efficacy
US9649375B2 (en) 2013-03-14 2017-05-16 The Administrators Of The Tulane Educational Fund Immunogenic peptide conjugate and method for inducing an anti-influenza therapeutic antibody response therewith
KR20140118682A (ko) * 2013-03-29 2014-10-08 (주)셀트리온 2 이상의 인플루엔자 ａ 바이러스 중화 결합 분자를 포함하는 조성물
WO2014191435A1 (en) 2013-05-30 2014-12-04 Crucell Holland B.V. Influenza virus vaccines and uses thereof
CN105848722B (zh) 2013-10-02 2021-09-03 免疫医疗有限责任公司 中和抗甲型流感抗体及其用途
RU2682049C2 (ru) * 2014-01-27 2019-03-14 Дженентек, Инк. Лечение вируса гриппа а h7n9
US10639370B2 (en) 2014-02-04 2020-05-05 Contrafect Corporation Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof
CA2938726A1 (en) * 2014-02-04 2015-08-13 Contrafect Corporation Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof
KR102378289B1 (ko) * 2014-02-10 2022-03-23 아이쥐엠 바이오사이언스 인코포레이티드 IgA 다중-특이적 결합 분자
BR112016022113A2 (pt) 2014-03-27 2017-10-31 Genentech Inc anticorpos anti-hemaglutinina do vírus influenza b e métodos de uso
KR101628331B1 (ko) * 2014-03-28 2016-06-08 주식회사 녹십자엠에스 인플루엔자 a 바이러스 특이적 단클론 항체 및 이를 이용한 인플루엔자 감염 치료 및 진단 방법
MY182440A (en) 2014-07-10 2021-01-25 Janssen Vaccines & Prevention Bv Influenza virus vaccines and uses thereof
AU2015286721B2 (en) 2014-07-10 2019-11-21 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
US10294292B2 (en) 2014-07-15 2019-05-21 Medimmune, Llc Neutralizing anti-influenza B antibodies and uses thereof
TWI701258B (zh) 2014-12-19 2020-08-11 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
EP3253411A1 (en) * 2015-02-05 2017-12-13 Janssen Vaccines & Prevention B.V. Binding molecules directed against influenza hemagglutinin and uses thereof
US10174127B2 (en) 2015-02-05 2019-01-08 Janssen Vaccines & Prevention B.V. Human neutralizing antibodies binding to influenza neuraminidase
US11135282B2 (en) * 2015-04-08 2021-10-05 Dana-Farber Cancer Institute, Inc. Humanized influenza monoclonal antibodies and methods of use thereof
EP3294753A1 (en) 2015-05-11 2018-03-21 Janssen Vaccines & Prevention B.V. Influenza virus neutralizing peptidomimetic compounds
EP3307310A2 (en) 2015-05-13 2018-04-18 The Trustees Of The University Of Pennsylvania Aav-mediated expression of anti-influenza antibodies and methods of use thereof
HUE056407T2 (hu) 2015-06-01 2022-02-28 Medimmune Llc Neutralizáló influenzaellenes kötõmolekulák és alkalmazásaik
EP3374390A1 (en) 2015-11-13 2018-09-19 Visterra, Inc. Compositions and methods for treating and preventing influenza
EP3402513A4 (en) 2016-01-13 2019-10-23 Medlmmune, LLC METHOD OF TREATING A FLU
EP3423484B1 (en) 2016-03-01 2021-01-13 Janssen Vaccines & Prevention B.V. Human neutralizing antibodies binding to influenza b neuraminidase
WO2017192589A1 (en) * 2016-05-02 2017-11-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to influenza ha and their use and identification
WO2018038096A1 (ja) * 2016-08-23 2018-03-01 国立大学法人東京大学 モノクローナル抗体又はその抗原結合フラグメント及びその使用
KR20190071714A (ko) 2016-10-27 2019-06-24 얀센 백신스 앤드 프리벤션 비.브이. 인플루엔자 바이러스 중화 화합물
WO2018138681A1 (en) * 2017-01-27 2018-08-02 National Research Council Of Canada Hemagglutinin-specific antibodies and uses thereof
US11040963B2 (en) 2017-02-02 2021-06-22 Janssen Vaccines & Prevention B.V. Piperazine derivatives for influenza virus inhibitions
WO2018141854A1 (en) 2017-02-02 2018-08-09 Janssen Vaccines & Prevention B.V. Piperazine derivatives for influenza virus inhibition
JOP20190200A1 (ar) 2017-02-28 2019-08-27 Univ Pennsylvania تركيبات نافعة في معالجة ضمور العضل النخاعي
SG10201912976WA (en) 2017-02-28 2020-02-27 Univ Pennsylvania Adeno-associated virus (aav) clade f vector and uses therefor
SG10201913833PA (en) 2017-02-28 2020-03-30 Univ Pennsylvania Influenza vaccines based on aav vectors
SG11202006399VA (en) 2018-01-23 2020-08-28 Janssen Vaccines & Prevention Bv Influenza virus vaccines and uses thereof
WO2019147867A1 (en) 2018-01-26 2019-08-01 Regeneron Pharmaceuticals, Inc. Human antibodies to influenza hemagglutinin
CN113924147A (zh) 2019-03-25 2022-01-11 威特拉公司 用于治疗和预防流感的组合物和方法
CA3152957A1 (en) * 2019-09-05 2021-03-11 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
US11642407B2 (en) 2020-02-28 2023-05-09 Massachusetts Institute Of Technology Identification of variable influenza residues and uses thereof
WO2021201677A1 (en) 2020-04-01 2021-10-07 Kiadis Pharma Intellectual Property B.V. Compositions and methods targeting influenza
US11175293B1 (en) 2021-01-04 2021-11-16 University Of Utah Research Foundation Rapid assay for detection of SARS-CoV-2 antibodies
EP4289826A1 (en) 2021-02-04 2023-12-13 Sichuan Haisco Pharmaceutical Co., Ltd. Salt and crystal form of ha inhibitor compound
WO2024104947A2 (en) 2022-11-14 2024-05-23 Janssen Vaccines & Prevention B.V. Influenza b virus vaccines and uses thereof
CN116589566A (zh) * 2022-11-18 2023-08-15 昆明医科大学第一附属医院 一种HIV-1中和抗体的改造重组单克隆IgM抗体及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
NL9101953A (nl) 1991-11-21 1993-06-16 Seed Capital Investments Testinrichting omvattende een plaat met een veelvoud van putjes met een bijbehorende doseerinrichting, alsmede een kit die deze inrichtingen omvat en toepassing van de inrichtingen.
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
DE69718341T2 (de) 1996-10-08 2003-10-30 Bisys B V U Verfahren und mittel zur auswahl von peptiden und proteinen mit spezifischer affinität zu einem zielmolekül
ATE447617T1 (de) 1999-04-15 2009-11-15 Crucell Holland Bv Verwendung von rekombinanten proteinen in menschlichen zellen
US7329530B2 (en) 2001-06-15 2008-02-12 Crucell Holland B.V. Chimaeric phages
EA017203B1 (ru) 2006-09-07 2012-10-30 Круселл Холланд Б.В. Связывающие молекулы человека, способные нейтрализовать вирус гриппа h5n1, и их применение
FR2921928B1 (fr) 2007-10-08 2011-03-04 Sanofi Pasteur Anticorps monoclonaux specifiques de l'hemagglutinine du virus grippal
WO2010010467A2 (en) 2008-07-25 2010-01-28 Institute For Research In Biomedicine Neutralizing anti-influenza a virus antibodies and uses thereof
EP2168987A1 (en) * 2008-09-22 2010-03-31 Mucosis B.V. Multifunctional linker protein containing an antibody against hemagglutinin, a conserved influenza antigen and an immunostimulating carrier binding domain
NZ596032A (en) 2009-05-11 2013-09-27 Crucell Holland Bv Human binding molecules capable of neutralizing influenza virus h3n2 and uses thereof
WO2013007770A1 (en) 2011-07-14 2013-01-17 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza a viruses of phylogenetic group 1 and phylogenetic group 2 and influenza b viruses

Also Published As

Publication number Publication date
DK2731967T3 (en) 2017-01-16
KR20140095017A (ko) 2014-07-31
IL230222A (en) 2017-09-28
JP5683752B2 (ja) 2015-03-11
NZ618530A (en) 2016-05-27
EA027054B1 (ru) 2017-06-30
IN2014CN00953A (hr) 2015-04-10
US9593159B2 (en) 2017-03-14
BR112014000263B1 (pt) 2022-01-18
EA201490288A1 (ru) 2014-05-30
BR112014000263A2 (pt) 2017-02-14
CA2838999C (en) 2021-02-16
CN103906763B (zh) 2016-10-12
JP2014527403A (ja) 2014-10-16
WO2013007770A1 (en) 2013-01-17
KR101941724B1 (ko) 2019-01-23
CA2838999A1 (en) 2013-01-17
EP2731967A1 (en) 2014-05-21
AU2012282504B2 (en) 2017-07-20
US20140120113A1 (en) 2014-05-01
MX346206B (es) 2017-03-09
ES2608321T3 (es) 2017-04-07
MX2014000373A (es) 2014-03-31
US8961978B2 (en) 2015-02-24
MY166282A (en) 2018-06-25
EP2731967B1 (en) 2016-10-12
US20150274811A1 (en) 2015-10-01
AU2012282504A1 (en) 2014-02-06
CN103906763A (zh) 2014-07-02

Similar Documents

Publication Publication Date Title
HRP20161740T1 (hr) Ljudske molekule za vezanje koje su sposobne neutralizirati viruse influence a filogenetske skupine 1 i filogenetske skupine 2, te viruse influence b
AR123305A2 (es) Proteínas de unión a antígeno
CO2018013500A2 (es) Anticuerpos anti-pd-l1 y usos de los mismos
HRP20201975T1 (hr) Neutralizirajuća protutijela anti-influenca a virusa i njihova uporaba
JP6711828B2 (ja) インフルエンザ赤血球凝集素に対するヒト抗体
PE20181270A1 (es) Anticuerpo que neutraliza el virus respiratorio sincitial humano
PH12016500859A1 (en) Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
JP2020500538A5 (hr)
JP2011528901A5 (hr)
JP2010521147A5 (hr)
HRP20130163T1 (hr) Ljudske molekule za vezanje koje mogu neutralizirati virus influence h5n1 i njihova uporaba
SI3042917T1 (en) PROTITELES AGAINST N3PGL AMILOID BETA PEPTID AND THEIR APPLICATION
JP2016503413A5 (hr)
ECSP16060104A (es) Anticuerpo pd-1, fragmento de unión al antígeno de este y uso médico de este
JP2014237714A5 (hr)
JP2015522252A5 (hr)
JP6371222B2 (ja) インフルエンザの受動免疫用抗体
AR109715A1 (es) Anticuerpos anti-cd27
JP2016502515A5 (hr)
JP2013531993A5 (hr)
EA201692530A1 (ru) Цитотоксические пептиды и их конъюгаты
EA202091590A1 (ru) Антитела против pd-l1 и варианты их применения
RU2017145268A (ru) Композиции и способы диагностики и лечения заболеваний, ассоциированных с дегенерацией нейритов
JP2014205674A5 (hr)
PE20161311A1 (es) Anticuerpos especificos del receptor del factor 1 de crecimiento similar a la insulina y usos de los mismos.